Search results

Found 7,460 pages
AUTHOR: Selina McKee

Your search yielded no results

  • Check if your spelling is correct.
  • Remove quotes around phrases to search for each word individually. bike shed will often show more results than "bike shed".
  • Consider loosening your query with OR. bike OR shed will often show more results than bike shed.

Pfizer’s Talzenna cleared for breast cancer

US regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with breast cancer carrying a certain mutation, identified by a companion diagnostic developed by Myriad. - News - PharmaTimes|US regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with breast cancer carrying a certain mutation, identified by a companion diagnostic developed by Myriad.|US regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with breast cancer carrying a certain mutation, identified by a companion diagnostic developed by Myriad.

by Selina McKee

www.pharmatimes.com/news/pfizers_talzenna_cleared_for_breast_cancer_1255951

NEJM publishes venetoclax/rituximab data

A combination of venetoclax and rituximab being developed by AbbVie and Roche/Genentech significantly improved progression-free survival (PFS) in patients with chronic lymphocytic leukaemia (CLL), shows data published by the New England Journal of Medicine. - News - PharmaTimes|A combination of venetoclax and rituximab being developed by AbbVie and Roche/Genentech significantly improved progression-free survival (PFS) in patients with chronic lymphocytic leukaemia (CLL), shows data published by the New England Journal of Medicine.|A combination of venetoclax and rituximab being developed by AbbVie and Roche/Genentech significantly improved progression-free survival (PFS) in patients with chronic lymphocytic leukaemia (CLL), shows data published by the New England Journal of Medicine.

by Selina McKee

www.pharmatimes.com/news/nejm_publishes_venetoclaxrituximab_data_1228818

Mallinckrodt to split business

UK-based specialty pharma group Mallinckrodt has unveiled plans to spin-off its specialty generics and active pharmaceutical ingredients business into a new company - News - PharmaTimes|UK-based specialty pharma group Mallinckrodt has unveiled plans to spin-off its specialty generics and active pharmaceutical ingredients business into a new company|UK-based specialty pharma group Mallinckrodt has unveiled plans to spin-off its specialty generics and active pharmaceutical ingredients business into a new company

by Selina McKee

www.pharmatimes.com/news/mallinckrodt_to_split_business_1272150

AstraZeneca eyeing up Medivation?

AstraZeneca is considering making a move on US group Medivation in a deal that could be worth around $7 billion, according to media reports.  - News - PharmaTimes|AstraZeneca is considering making a move on US group Medivation in a deal that could be worth around $7 billion, according to media reports. |AstraZeneca is considering making a move on US group Medivation in a deal that could be worth around $7 billion, according to media reports. 

by Selina McKee

www.pharmatimes.com/news/astrazeneca_eyeing_up_medivation_1020475

MSD pulls EU filing for Keytruda combo

MSD has pulled back its application to market Keytruda (pembrolizumab) in the European Union in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC). - News - PharmaTimes|MSD has pulled back its application to market Keytruda (pembrolizumab) in the European Union in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC).|MSD has pulled back its application to market Keytruda (pembrolizumab) in the European Union in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC).

by Selina McKee

www.pharmatimes.com/news/msd_pulls_eu_filing_for_keytruda_combo_1209845

GSK names new chief executive

GlaxoSmithKline has announced that Emma Walmsley will take over from current chief executive Andrew Witty following his retirement at the end of March next year. - News - PharmaTimes|GlaxoSmithKline has announced that Emma Walmsley will take over from current chief executive Andrew Witty following his retirement at the end of March next year.|GlaxoSmithKline has announced that Emma Walmsley will take over from current chief executive Andrew Witty following his retirement at the end of March next year.

by Selina McKee

www.pharmatimes.com/news/gsk_names_new_chief_executive_1137962

EU clears Roche’s Ocrevus for MS

Roche’s Ocrevus has been approved for use in Europe to treat adults with relapsing multiple sclerosis (RMS) and early primary progressive multiple sclerosis (PPMS). - News - PharmaTimes|Roche’s Ocrevus has been approved for use in Europe to treat adults with relapsing multiple sclerosis (RMS) and early primary progressive multiple sclerosis (PPMS).|Roche’s Ocrevus has been approved for use in Europe to treat adults with relapsing multiple sclerosis (RMS) and early primary progressive multiple sclerosis (PPMS).

by Selina McKee

www.pharmatimes.com/news/eu_clears_roches_ocrevus_for_ms_1216747

Takeda licenses Crescendo’s Humabodies

Japanese drug giant Takeda has taken an exclusive license to Cambridge, UK-based Crescendo Biologics’ Humabodies directed to one of its oncology targets. - News - PharmaTimes|Japanese drug giant Takeda has taken an exclusive license to Cambridge, UK-based Crescendo Biologics’ Humabodies directed to one of its oncology targets.|Japanese drug giant Takeda has taken an exclusive license to Cambridge, UK-based Crescendo Biologics’ Humabodies directed to one of its oncology targets.

by Selina McKee

www.pharmatimes.com/news/takeda_licenses_crescendos_humabodies_1258680

FDA rejects Sunovion’s ADHD drug

Sunovion’s application to market dasotraline for the treatment of attention-deficit hyperactivity disorder (ADHD) has been rejected by US regulators. - News - PharmaTimes|Sunovion’s application to market dasotraline for the treatment of attention-deficit hyperactivity disorder (ADHD) has been rejected by US regulators.|Sunovion’s application to market dasotraline for the treatment of attention-deficit hyperactivity disorder (ADHD) has been rejected by US regulators.

by Selina McKee

www.pharmatimes.com/news/fda_rejects_sunovions_adhd_drug_1251093

AI app decreases symptoms of COPD, study finds

A new clinical study has found that Kaia Health’s artificial intelligence app successfully decreases symptoms of Chronic Obstructive Pulmonary Disease (COPD). - News - PharmaTimes|A new clinical study has found that Kaia Health’s artificial intelligence app successfully decreases symptoms of Chronic Obstructive Pulmonary Disease (COPD).|A new clinical study has found that Kaia Health’s artificial intelligence app successfully decreases symptoms of Chronic Obstructive Pulmonary Disease (COPD).

by Selina McKee

www.pharmatimes.com/news/ai_app_decreases_symptoms_of_copd,_study_finds_1272387

Latest jobs

View all

What job are you looking for?

This field is required.

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download